Peer-reviewed veterinary case report
Pax5 as a new marker for diagnosing canine B-cell lymphoma
By S. Sirivisoot et al.·Published in Veterinární Medicína·2017·Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand, CZ·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pax5 as a potential candidate marker for canine B-cell lymphoma
- Species:
- dog
Plain-English summary
A study looked at how well a specific marker called Pax5 can help identify B-cell lymphoma in dogs. Researchers examined 46 cases of lymphoma, finding that Pax5 was effective in identifying B-cell lymphomas, which made up about 70% of the cases. This marker was found to be more reliable than another common marker, CD79a. The findings suggest that using both Pax5 and CD3 (a marker for T-cells) can improve the diagnosis and classification of lymphomas in dogs, helping veterinarians provide better treatment options.
People also search for: dog lymphoma symptoms · B-cell lymphoma treatment in dogs · what is Pax5 in dogs
Abstract
Immunophenotyping is a valuable method for prognosis in canine malignant lymphoma. The general B-cell marker is CD79a; however, Pax5 or B-cell specific activator protein, a transcription factor that controls B-cell identity and cell maturation, could also be used as a B-cell indicator in canine lymphomas. This study aimed to use Pax5, CD79a and CD3 expression in immunohistochemistry of spontaneous canine lymphomas, in order to carry out diagnosis and histopathological classification according to the World Health Organization guidelines. Forty-six retrospective cases including 33 multicentric, eight extranodal, and five alimentary lymphomas in dogs were immunostained by anti-Pax5 and anti-CD79a antibodies for B-cell identification, and anti-CD3 antibody for T-cell identification. T-cell lymphomas (CD3+/Pax5-/CD79a-) accounted for 30.43% of cases (14/46), and four of the lymphomas (28.57%) presented with CD3+/Pax5-/CD79a+. Conversely, B-cell lymphomas (CD3-/Pax5+/CD79a+) accounted for 69.57% of cases (32/46) and 12.5% of these (4/32) showed only Pax5-positive cells (CD3-/Pax5+/CD79a-). Therefore, in dogs, Pax5 appears to be a more useful marker for staining all B-cell subtypes compared to CD79a. Immunophenotyping with both Pax5 and CD3 are necessary for lymphoid lineage identification in canine lymphomas.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.17221/100/2016-VETMED